Roman Rösemann
YOU?
Author Swipe
View article: 525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors
525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors Open
Background The intravenously administered small-molecule Toll-like receptor 7 (TLR7) agonist BNT411 was developed to systemically activate plasmacytoid dendritic cells, characterized by a Type 1 interferon-dominated release of cytokines. T…
View article: Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response
Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response Open
TLR7 agonists are considered promising drugs for cancer therapy. The currently available compounds are not well tolerated when administered intravenously and therefore are restricted to disease settings amenable for topical application. He…
View article: Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria
Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria Open
Nature Communications 8 Article number:14193 (2017); Published 31 January 2017; Updated 6 Apr 2017 This Article contains errors in Figs. 1 and 8 that were introduced during the production process. The compound on the lower right side of Fi…